卡博赞提尼布诱导的血清肌酸激酶升高和狂犬病:一个回顾性的病例系列
Taro Yamanaka1, Kohji Takemura1, Michikata Hayashida2
1Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, 105-8470, Japan.
对于晚期细胞癌 (RCC) 的卡博赞提尼布治疗可以导致超过一半的患者的肌酸激酶 (CK) 升高. 虽然往往无症状,但有些人可能会发生狂肌痛,需要医疗照顾.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 轮骨髓溶解是一种严重的疾病,其特征是肌酸激酶 (CK) 水平升高.
- 药物诱导的狂体痛是各种药物的已知并发症.
- 卡博桑提尼布是晚期细胞癌 (RCC) 的标准治疗方法.
研究的目的:
- 在RCC患者中确定卡博赞提尼布诱导的CK升高和拉布多米解的频率.
- 描述这些事件的临床特征.
主要方法:
- 对13名以卡博赞提尼布单独治疗的晚期RCC患者的回顾性评估.
- 从2020年4月到2023年4月的临床信息和实验室数据的分析.
- 主要终点:CK升高的频率和拉布地质溶解.
主要成果:
- 在13名患者中有8名 (61.5%) 发生了血清CK升高.
- 在开始卡博赞提尼布后的14天中,CK的升高发生了.
- 两名患者出现了肌肉衰弱和/或急性损伤的狂肠分裂.
结论:
- 在RCC治疗卡博赞提尼布期间,CK升高是经常发生的.
- 大多数CK升高无症状,不具有临床意义.
- 临床医生应监测症状性狂犬病,偶尔可能发生.
更多相关视频
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease II: Clinical Manifestations
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury I: Introduction
